Nivolumab Combination Therapy for the Treatment of Unresectable Advanced or Metastatic Oesophageal Squamous Cell Carcinoma

Oesophageal cancer (OC) is the seventh most common malignancy worldwide, and there are few effective treatment options for advanced OC. Fluoropyrimidine platinum-based chemotherapy has been standard first-line oesophageal squamous cell carcinoma (OSCC) but survival outcomes poor. Therefore, a need to develop new, more drugs. Immune checkpoint inhibitors (ICIs) have emerged as new several malignancies. Nivolumab, human monoclonal immunoglobulin G4 antibody that inhibits programmed death protein-1, developed of OSCC. Nivolumab monotherapy demonstrated clinical efficacy safety in patients with OSCC ATTRACTION-3 trial, was approved by United States Food Drug Administration later-line previously treated OSCC, regardless protein-1 ligand expression status. Recently, CheckMate 648 trial both an ICI combination chemotherapy, dual combination, This review discusses current status nivolumab therapy future perspectives.